X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Coave lead program HCTx-PDE6b (AAV2/5-hPDE6B), an AAV5-based gene replacement therapy, is being evaluated in a Phase I/II trial for the treatment of retinitis pigmentosa.
Lead Product(s): AAV2/5-hPDE6B
Therapeutic Area: Genetic Disease Product Name: CTx-PDE6b
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2024
Details:
The funding will support Coave to focus on the development of CTx-TFEB, which utilizes a coAAV vector to deliver a gene sequence encoding functional TFEB transcription factor. It is being evaluated in preclinical studies for the treatment of multiple System Atrophy.
Lead Product(s): CTx-TFEB
Therapeutic Area: Neurology Product Name: CTx-TFEB
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: ALS Association
Deal Size: $2.9 million Upfront Cash: Undisclosed
Deal Type: Funding February 29, 2024
Details:
CTx-PDE6b is a clinical stage AAV5-based gene therapy for the treatment of retinitis pigmentosa (RP) caused by bi-allelic mutations of the PDE6b gene. There are currently no approved treatments for PDE6b RP.
Lead Product(s): AAV2/5-hPDE6B
Therapeutic Area: Genetic Disease Product Name: CTx-PDE6b
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
The collaboration will explore the development of gene therapy product CTx-TFEB, targeting the transcription factor EB (TFEB) for the treatment of alpha-synucleinopathies, such as Multiple System Atrophy (MSA) and idiopathic Parkinson’s disease (PD).
Lead Product(s): CTx-TFEB
Therapeutic Area: Neurology Product Name: CTx-TFEB
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Institute of Neurodegenerative Diseases of Bordeaux
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 14, 2022
Details:
Under the two-stage collaboration both companies will initially combine their complementary expertise to co-develop manufacturing technologies for AAV-based gene therapy products including CTx-GBA1.
Lead Product(s): CTx-GBA1
Therapeutic Area: Neurology Product Name: CTx-GBA1
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: ABL
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 09, 2022
Details:
Coave and Théa will co-develop CTx-PDE6b under the joint agreement. Coave retains rights to commercialize CTx-PDE6b in the US and Théa receives an exclusive license to commercialize CTx-PDE6b in Europe (EU27), Ukraine, Turkey, Russia and North Africa.
Lead Product(s): CTx-PDE6b
Therapeutic Area: Genetic Disease Product Name: HORA-PDE6b
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Laboratoires Thea
Deal Size: $87.3 million Upfront Cash: $11.6 million
Deal Type: Licensing Agreement September 16, 2021
Details:
Coave Therapeutics will use the proceeds to support: its lead clinical program CTx-PDE6b; Developing its AAV Ligand Conjugate platform; Developing its AAV Ligand Conjugate (‘ALIGATER’) platform; Partnerships in key disease areas to progress novel coAAV candidates.
Lead Product(s): CTx-PDE6b
Therapeutic Area: Ophthalmology Product Name: CTx-PDE6b
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Seroba Life Sciences
Deal Size: $39.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing July 21, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
